1. Show article details.

    Largest Dutch pension fund exits Mylan over death penalty concerns

    Reuters – 4:25 AM ET 08/29/2015

    The Dutch public employees' pension fund, the world's third largest, has sold all its shares in pharmaceuticals maker Mylan after it emerged that one of its products is in stock at a United States prison where death sentences are carried out.

  2. Show article details.

    Mylan shareholders back Perrigo takeover, tender offer up next

    Reuters – 8:32 AM ET 08/28/2015

    Mylan NV (MYL) shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co (PRGO), allowing it to launch a tender offer for the company's shares in the next few weeks. Mylan said that it had the support from investors representing a majority of shares, passing the threshold it needed to go directly to Perrigo (PRGO) shareholders.

  3. Show article details.

    Mylan's Holders Approve Perrigo Purchase

    DJ Business News – 8:05 AM ET 08/28/2015

    Mylan NV (MYL) shareholders voted Friday in favor of the company's $35.6 billion bid for Perrigo Co. (PRGO), handing the generic- drug maker ammunition for an attempted hostile takeover of its rival. The bid won approval from two-thirds of votes cast at a shareholder meeting, Mylan said Friday, adding that it got support from more than a majority of the company's shares outstanding. It wasn't more specific on the tally.

  4. Show article details.

    Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction

    PR Newswire – 8:03 AM ET 08/28/2015

    DUBLIN, Aug. 28, 2015 Perrigo Company plc (PRGO) today commented on the Mylan N.V. (MYL) shareholder vote regarding its planned unsolicited offer to acquire Perrigo.

  5. Show article details.

    Mylan shareholders approve acquisition of Perrigo

    MarketWatch – 7:47 AM ET 08/28/2015

    Mylan N.V. (MYL) said Friday that its shareholders have approved its proposed $35.6 billion takeover of Perrigo Company PLC (PRGO) and it will launch a formal offer soon. A representative from Perrigo (PRGO) could not immediately be reached for comment. The proposed deal--which has been swiftly opposed by Perrigo (PRGO) at every turn--was approved by more than two- thirds of shareholders at a general meeting.

  6. Show article details.

    Mylan says shareholders back Perrigo takeover

    Reuters – 7:42 AM ET 08/28/2015

    Mylan NV (MYL) shareholders on Friday backed the drugmaker's hostile bid for Perrigo Co (PRGO), allowing it to launch a tender offer for the company's shares in the next few weeks. Mylan said that more than two-thirds of shareholders had backed the vote.

  7. Show article details.

    Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo

    PR Newswire – 7:21 AM ET 08/28/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2015  Mylan N.V. (MYL) today announced that its shareholders have approved Mylan's proposed acquisition of Perrigo Company plc (PRGO) and the related issuance of Mylan ordinary shares to Perrigo's (PRGO) shareholders at an extraordinary general meeting of shareholders held today.

  8. Show article details.

    What to Watch in the Day Ahead - Friday, Aug. 28

    Reuters – 2:37 PM ET 08/27/2015

    U.S. consumer spending, which accounts for more than two-thirds of economic activity, is likely to have increased by 0.4 percent in July from its previous month's reading of 0.2 percent.

  9. Show article details.

    Mylan Confirms the U.S. Patent and Trademark Office Institutes Inter Partes Review Proceedings against Two Copaxone® 40 mg/mL Dosing Patents

    PR Newswire – 2:59 PM ET 08/25/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015  Mylan N.V. (MYL) today announced that the U.S. Patent and Trademark Office has instituted inter partes review proceedings against two Copaxone® 40 mg/mL patents, U.S. Patent Nos.

  10. Show article details.

    Mylan Launches Generic Zosyn® Injection

    PR Newswire – 2:13 PM ET 08/25/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015  Mylan N.V. (MYL) today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's Zosyn® Injection.

  11. Show article details.

    Mylan Comments on Misleading Statements Made by Perrigo

    PR Newswire – 1:20 PM ET 08/25/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2015  Mylan N.V. (MYL) today commented on the misleading statements made by Perrigo Company plc (PRGO) in relation to Mylan's offer to acquire Perrigo.

  12. Show article details.

    BRIEF-Irish Takeover Panel says Perrigo's Aug 13 statement breached rule

    Reuters – 11:12 AM ET 08/25/2015

    Irish Takeover Panel. * Ruled Perrigo's Aug 13 statement "Mylan already proposed a dilutive deal that substantially undervalues Perrigo" breached rule. * Perrigo's (PRGO) statement breached rule 19.3 as it was unclear that term "dilutive" described effect on Mylan shareholders Source text for Eikon:

  13. Show article details.

    Mylan Clarifies Certain Inaccuracies by Third Parties Related to Lowered Acceptance Condition to Acquire Perrigo

    PR Newswire – 3:19 PM ET 08/21/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 21, 2015  Mylan N.V. (MYL) today clarified certain inaccuracies by third parties related to Mylan having lowered the acceptance condition in its offer to acquire Perrigo Company plc (PRGO) from not less than 80% of Perrigo (PRGO) ordinary shares to greater than 50% of Perrigo (PRGO) ordinary shares.

  14. Show article details.

    Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities

    PR Newswire – 11:31 AM ET 08/18/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 Mylan N.V. (MYL) today commented on a warning letter issued by the U.S. Food and Drug Administration on Aug. 6, 2015, relating to its Agila Specialty Formulation Facility, Sterile Product Division, and Onco Therapies Limited sites in India.

  15. Show article details.

    Mylan Confirms First-to-File Patent Challenge Relating to Zytiga®

    PR Newswire – 7:30 AM ET 08/18/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015  Mylan N.V. (MYL) today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg.

  16. Show article details.

    Proxy firm urges Mylan investors vote 'no'; Paulson backs deal

    Reuters – 2:30 PM ET 08/14/2015

    ISS Proxy Advisory Services recommended on Friday that its clients vote against Mylan NV's (MYL) $30 billion hostile takeover of Perrigo Co (PRGO), even as Mylan's largest hedge fund investor put its money behind the combination. Paulson & Co, which owns a 4.6 percent stake in Mylan, said it voted for the generic drugmaker to pursue its tender offer for Perrigo (PRGO) shares.

  17. Show article details.

    Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo

    PR Newswire – 1:30 PM ET 08/14/2015

    NEW YORK, Aug. 14, 2015 On behalf of funds that it manages, Paulson & Co. today voted all of its 21.9 million Mylan shares in support of the proposed merger with Perrigo.

  18. Show article details.

    ISS Affirms Perrigo's Position That Proposed Mylan Transaction Would Be Value Destructive

    PR Newswire – 11:07 AM ET 08/14/2015

    DUBLIN, Aug. 14, 2015 Perrigo Company plc (PRGO) today announced that Institutional Shareholder Services, the leading independent proxy advisory firm, recommended that Mylan NV (MYL) shareholders vote "AGAINST" the unsolicited offer to acquire all of the outstanding shares of Perrigo (PRGO) for $75.00 per share in cash and 2.3 Mylan ordinary shares for each ordinary Perrigo (PRGO) share.

  19. Show article details.

    Mylan Responds to ISS Recommendation Regarding Perrigo Transaction

    PR Newswire – 9:18 AM ET 08/14/2015

    HERTFORDSHIRE, England and PITTSBURGH, Aug. 14, 2015  Mylan N.V. (MYL) today issued the following statement in response to the report issued by Institutional Shareholder Services regarding Mylan's proposed acquisition of Perrigo Company plc.

  20. Show article details.

    Proxy firm ISS advises Mylan investors to vote no on Perrigo buy

    Reuters – 8:57 AM ET 08/14/2015

    ISS Proxy Advisory Services on Friday recommended that its institutional investor clients vote against Mylan NV's (MYL) $34 billion hostile takeover offer of Perrigo Co (PRGO) saying that it would result in significant dilution. ISS's recommendation veered in the opposite direction from two other proxy advisory firms which earlier this week advised clients to vote for the deal.

Page:

Today's and Upcoming Events

  • Oct
    29

    MYL to announce Q3 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Aug
    28

    Shareholders Meeting

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.